Aligos Therapeutics (ALGS) Competitors $8.90 +0.22 (+2.48%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. OGI, NLTX, PROK, ALMS, ELDN, CYBN, TIL, PBYI, VYGR, and TLSAShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Organigram Global (OGI), Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), Eledon Pharmaceuticals (ELDN), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Organigram Global Neoleukin Therapeutics ProKidney Alumis Eledon Pharmaceuticals Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences Organigram Global (NASDAQ:OGI) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings. Is OGI or ALGS more profitable? Organigram Global has a net margin of 8.05% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Organigram Global's return on equity.Company Net Margins Return on Equity Return on Assets Organigram Global8.05% -5.93% -4.39% Aligos Therapeutics -1,628.75%14.67%7.19% Do analysts prefer OGI or ALGS? Aligos Therapeutics has a consensus price target of $70.00, indicating a potential upside of 687.49%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, OGI or ALGS? Organigram Global has higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram Global$117.47M1.67-$33.39M$0.1014.65Aligos Therapeutics$3.94M13.78-$131.21M-$17.51-0.51 Do insiders & institutionals hold more shares of OGI or ALGS? 34.6% of Organigram Global shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 0.1% of Organigram Global shares are owned by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, OGI or ALGS? Organigram Global has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Does the media refer more to OGI or ALGS? In the previous week, Organigram Global and Organigram Global both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 0.94 beat Organigram Global's score of 0.62 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram Global 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAligos Therapeutics beats Organigram Global on 10 of the 15 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.02M$2.93B$5.50B$9.40BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.5020.2928.1319.86Price / Sales13.78259.75424.9198.68Price / CashN/A42.3835.5357.53Price / Book-1.197.808.235.71Net Income-$131.21M-$55.11M$3.24B$257.80M7 Day Performance1.13%2.34%0.66%1.12%1 Month Performance18.05%13.02%8.07%11.30%1 Year Performance-31.00%1.46%28.44%16.88% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.1607 of 5 stars$8.89+2.4%$70.00+687.5%-34.0%$54.02M$3.94M-0.5090OGIOrganigram Global1.1388 of 5 stars$1.39-2.8%N/A-16.6%$191.53M$117.47M13.90860Gap DownNLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-53.1%$188.81MN/A-6.4690PROKProKidney3.3765 of 5 stars$0.61-4.8%$3.50+477.1%+54.8%$186.51M$306K-1.013Analyst ForecastGap UpALMSAlumis3.2757 of 5 stars$3.31-2.6%$22.86+590.5%-69.0%$184.98MN/A0.00N/AELDNEledon Pharmaceuticals1.9955 of 5 stars$3.11+1.0%$9.00+189.4%+33.6%$184.44MN/A-1.4810Positive NewsAnalyst RevisionCYBNCybin2.8283 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050News CoverageTILInstil Bio3.4439 of 5 stars$23.64-14.0%$119.00+403.4%+94.1%$180.37MN/A-1.97410High Trading VolumePBYIPuma Biotechnology4.2268 of 5 stars$3.54-1.1%$7.00+97.7%-12.9%$177.68M$230.50M4.60200VYGRVoyager Therapeutics4.0135 of 5 stars$3.04-5.0%$13.39+340.5%-64.0%$177.08M$80M-2.08100News CoverageTLSATiziana Life Sciences1.171 of 5 stars$1.53+1.3%N/A+85.2%$176.44MN/A0.008 Related Companies and Tools Related Companies Organigram Global Competitors Neoleukin Therapeutics Competitors ProKidney Competitors Alumis Competitors Eledon Pharmaceuticals Competitors Cybin Competitors Instil Bio Competitors Puma Biotechnology Competitors Voyager Therapeutics Competitors Tiziana Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALGS Stock Alerts